The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Vesicle Permeabilization by Protofibrillar α-Synuclein: Implications for the Pathogenesis and Treatment of Parkinson's Disease
Abstract
Fibrillar alpha-synuclein is a component of the Lewy body, the characteristic neuronal inclusion of the Parkinson's disease (PD) brain. Both alpha-synuclein mutations linked to autosomal dominant early-onset forms of PD promote the in vitro conversion of the natively unfolded protein into ordered prefibrillar oligomers, suggesting that these protofibrils, rather than the fibril itself, may induce cell death. We report here that protofibrils differ markedly from fibrils with respect to their interactions with synthetic membranes. Protofibrillar alpha-synuclein, in contrast to the monomeric and the fibrillar forms, binds synthetic vesicles very tightly via a beta-sheet-rich structure and transiently permeabilizes these vesicles. The destruction of vesicular membranes by protofibrillar alpha-synuclein was directly observed by atomic force microscopy. The possibility that the toxicity of alpha-synuclein fibrillization may derive from an oligomeric intermediate, rather than the fibril, has implications regarding the design of therapeutics for PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemical Pathways of Caspase Activation During Apoptosis
Budihardjo, I., Oliver, H., Lutter, M., Luo, X., & Wang, X. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.269 · Cited by 2,565
Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal
Maroteaux, L., Campanelli, J., & Scheller, R. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02804.1988 · Cited by 1,641
Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes
Davidson, W. S., Jonas, A., Clayton, D. F., & George, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.9443 · Cited by 1,585
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Self-citationETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Hartley, D. M., Walsh, D. M., Ye, C. P., Diehl, T., Vasquez, S., Vassilev, P. M., Teplow, D. B., & Selkoe, D. J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-20-08876.1999 · Cited by 817
Conway, K. A., Harper, J. D., & Lansbury, P. T. (2000) · Biochemistry · doi:10.1021/bi991447r · Cited by 786
Self-citationRugar, D., & Hansma, P. (1990) · Physics Today · doi:10.1063/1.881238 · Cited by 589
Giasson, B. I., Uryu, K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7619 · Cited by 507
Contribution of somal Lewy bodies to neuronal death
Tompkins, M. M., & Hill, W. D. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00874-3 · Cited by 183
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Self-citationCaughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
Self-citationIn vivo demonstration that α-synuclein oligomers are toxic
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100976108 · Cited by 1,463
Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein
Lotharius, J., & Brundin, P. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn983 · Cited by 1,283
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., Stefanis, L., & Vekrellis, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5699-09.2010 · Cited by 1,115
“…which greatly compromises membrane integrity, and lead to neuronal degeneration via the creation of significant alterations in the equilibrium of ions and small metabolites between the cytoplasm and the extracellular space (Heiser et al., 2000; Volles et al., 2001; Volles and Lansbury, 2003).”
BackgroundBendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding
Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., & Kostka, M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2617-07.2007 · Cited by 765
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease
Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.004 · Cited by 762
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Amyloidogenic Protein–Membrane Interactions: Mechanistic Insight from Model Systems
Butterfield, S. M., & Lashuel, H. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200906670 · Cited by 592
DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation
Shendelman, S., Jonason, A., Martinat, C., Leete, T., & Abeliovich, A. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020362 · Cited by 590
Kirkitadze, M. D., Bitan, G., & Teplow, D. B. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10328 · Cited by 585
Cell Biology and Pathophysiology of α-Synuclein
Burré, J., Sharma, M., & Südhof, T. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024091 · Cited by 579
Asanuma, M., Miyazaki, I., & Ogawa, N. (2003) · Neurotoxicity Research · doi:10.1007/bf03033137 · Cited by 516
Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald, A., & Lotharius, J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.01.013 · Cited by 508
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
Hashimoto, M., Rockenstein, E., Crews, L., & Masliah, E. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:21 · Cited by 501
The Aggregation and Fibrillation of α-Synuclein
Fink, A. L. (2006) · Accounts of Chemical Research · doi:10.1021/ar050073t · Cited by 501
Uversky, V. N. (2003) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2003.10506918 · Cited by 500
Lo Bianco, C., Ridet, J.-L., Schneider, B. L., Déglon, N., & Aebischer, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152339799 · Cited by 482
The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils
Zhu, M., Rajamani, S., Kaylor, J., Han, S., Zhou, F., & Fink, A. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403129200 · Cited by 473
Calcium signaling and neurodegenerative diseases
Bezprozvanny, I. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.001 · Cited by 469
Chen, S. W., Drakulic, S., Deas, E., Ouberai, M., Aprile, F. A., Arranz, R., Ness, S., Roodveldt, C., Guilliams, T., De-Genst, E. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421204112 · Cited by 460
Lee, H.-J., Choi, C., & Lee, S.-J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107045200 · Cited by 450
Self-citationClearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
Lee, H.-J., Khoshaghideh, F., Patel, S., & Lee, S.-J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3809-03.2004 · Cited by 445
Self-citationModification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior
Mattson, M. P., Chan, S. L., & Duan, W. (2002) · Physiological Reviews · doi:10.1152/physrev.00004.2002 · Cited by 439
Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases)
Kozlowski, H., Luczkowski, M., Remelli, M., & Valensin, D. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.013 · Cited by 437
Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein
Cole, N. B., Murphy, D. D., Grider, T., Rueter, S., Brasaemle, D., & Nussbaum, R. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108414200 · Cited by 430
Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein
Willingham, S., Outeiro, T. F., DeVit, M. J., Lindquist, S. L., & Muchowski, P. J. (2003) · Science · doi:10.1126/science.1090389 · Cited by 422
Molecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna-Reeves, C. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129001 · Cited by 415
Congo red and protein aggregation in neurodegenerative diseases
Frid, P., Anisimov, S. V., & Popovic, N. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.08.001 · Cited by 402
The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?
Lashuel, H. A., & Lansbury, P. T. (2006) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583506004422 · Cited by 400
Self-citationProteasomal Inhibition by α-Synuclein Filaments and Oligomers
Lindersson, E., Beedholm, R., Højrup, P., Moos, T., Gai, W., Hendil, K. B., & Jensen, P. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306390200 · Cited by 397
Multiple Tight Phospholipid-Binding Modes of α-Synuclein Revealed by Solution NMR Spectroscopy
Bodner, C. R., Dobson, C. M., & Bax, A. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.05.066 · Cited by 376
Uversky, V. N. (2009) · The Protein Journal · doi:10.1007/s10930-009-9201-4 · Cited by 360
Pathological roles of α-synuclein in neurological disorders
Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., & Stefanis, L. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70213-7 · Cited by 357
The relevance of iron in the pathogenesis of Parkinson’s disease
Sian‐Hülsmann, J., Mandel, S., Youdim, M. B. H., & Riederer, P. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 352
Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line
Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., & Brundin, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205518200 · Cited by 352
Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders
Ingelsson, M. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00408 · Cited by 344
The Relevance of Iron in the Pathogenesis of Parkinson's Disease
GÖTZ, M. E., DOUBLE, K., GERLACH, M., YOUDIM, M. B. H., & RIEDERERE, P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.017 · Cited by 342
Understanding the molecular causes of Parkinson's disease
Wood-Kaczmar, A., Gandhi, S., & Wood, N. W. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.09.007 · Cited by 327
Zhu, M., Li, J., & Fink, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305326200 · Cited by 323
Lo Bianco, C., Schneider, B. L., Bauer, M., Sajadi, A., Brice, A., Iwatsubo, T., & Aebischer, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405313101 · Cited by 322
Danzer, K. M., Ruf, W. P., Putcha, P., Joyner, D., Hashimoto, T., Glabe, C., Hyman, B. T., & McLean, P. J. (2011) · The FASEB Journal · doi:10.1096/fj.10-164624 · Cited by 312
Phospholipid-Cytochrome c Interaction
Tuominen, E. K. J., Wallace, C. J. A., & Kinnunen, P. K. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200056200 · Cited by 309
Sevlever, D., Jiang, P., & Yen, S.-H. C. (2008) · Biochemistry · doi:10.1021/bi800699v · Cited by 305
Oxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300
Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking
Choi, B.-K., Choi, M.-G., Kim, J.-Y., Yang, Y., Lai, Y., Kweon, D.-H., Lee, N. K., & Shin, Y.-K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218424110 · Cited by 300
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons
Lundblad, M., Decressac, M., Mattsson, B., & Björklund, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200575109 · Cited by 292
α‐Synuclein oligomers and clinical implications for Parkinson disease
Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E. (2013) · Annals of Neurology · doi:10.1002/ana.23746 · Cited by 292
Freeman, D., Cedillos, R., Choyke, S., Lukic, Z., McGuire, K., Marvin, S., Burrage, A. M., Sudholt, S., Rana, A., O'Connor, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062143 · Cited by 289
Mutation E46K increases phospholipid binding and assembly into filaments of human α‐synuclein
Choi, W., Zibaee, S., Jakes, R., Serpell, L. C., Davletov, B., Anthony Crowther, R., & Goedert, M. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.038 · Cited by 286
Functional Consequences of α-Synuclein Tyrosine Nitration
Hodara, R., Norris, E. H., Giasson, B. I., Mishizen-Eberz, A. J., Lynch, D. R., Lee, V. M.-Y., & Ischiropoulos, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408906200 · Cited by 286
Secondary Structure of α-Synuclein Oligomers: Characterization by Raman and Atomic Force Microscopy
Apetri, M. M., Maiti, N. C., Zagorski, M. G., Carey, P. R., & Anderson, V. E. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.10.071 · Cited by 283
Tsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003135 · Cited by 281
RetractedUnfoldomics of human diseases: linking protein intrinsic disorder with diseases
Uversky, V. N., Oldfield, C. J., Midic, U., Xie, H., Xue, B., Vucetic, S., Iakoucheva, L. M., Obradovic, Z., & Dunker, A. K. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-s1-s7 · Cited by 281
Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S., & Selkoe, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.545749 · Cited by 279
Plasma membrane integrity in health and disease: significance and therapeutic potential
Dias, C., & Nylandsted, J. (2021) · Cell Discovery · doi:10.1038/s41421-020-00233-2 · Cited by 278
Roberts, R. F., Wade-Martins, R., & Alegre-Abarrategui, J. (2015) · Brain · doi:10.1093/brain/awv040 · Cited by 271
Lotharius, J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2395 · Cited by 269
The role of lipid–protein interactions in amyloid-type protein fibril formation
Gorbenko, G. P., & Kinnunen, P. K. J. (2006) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2006.02.006 · Cited by 267
Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
Dev, K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 263
Higgins, C. M., Jung, C., & Xu, Z. (2003) · BMC Neuroscience · doi:10.1186/1471-2202-4-16 · Cited by 262
Therapeutic strategies for human amyloid diseases
Sacchettini, J. C., & Kelly, J. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd769 · Cited by 261
Sparr, E., Engel, M. F. M., Sakharov, D. V., Sprong, M., Jacobs, J., de Kruijff, B., Höppener, J. W. M., & Antoinette Killian, J. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.075 · Cited by 257
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Quantification of α-Synuclein Binding to Lipid Vesicles Using Fluorescence Correlation Spectroscopy
Rhoades, E., Ramlall, T. F., Webb, W. W., & Eliezer, D. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.079251 · Cited by 257
Surface-catalyzed Amyloid Fibril Formation
Zhu, M., Souillac, P. O., Ionescu-Zanetti, C., Carter, S. A., & Fink, A. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207225200 · Cited by 256
The Role of Stable α-Synuclein Oligomers in the Molecular Events Underlying Amyloid Formation
Lorenzen, N., Nielsen, S. B., Buell, A. K., Kaspersen, J. D., Arosio, P., Vad, B. S., Paslawski, W., Christiansen, G., Valnickova-Hansen, Z., Andreasen, M., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411577t · Cited by 255
Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus
Ashraf, G., Greig, N., Khan, T., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I., Zaidi, S., Akram, M., Jabir, N., et al. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917095514 · Cited by 236
Tau Oligomers Impair Artificial Membrane Integrity and Cellular Viability
Flach, K., Hilbrich, I., Schiffmann, A., Gärtner, U., Krüger, M., Leonhardt, M., Waschipky, H., Wick, L., Arendt, T., & Holzer, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396176 · Cited by 188
α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration
Mosharov, E. V., Staal, R. G. W., Bové, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M. H., Troyer, M. D., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0519-06.2006 · Cited by 165
Minocycline Enhances MPTP Toxicity to Dopaminergic Neurons
Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10709 · Cited by 158
Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148
Burke, K. A., Yates, E. A., & Legleiter, J. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00017 · Cited by 127
Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
ROCKENSTEIN, E., CREWS, L., & MASLIAH, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.013 · Cited by 65
Development of FABP3 ligands that inhibit arachidonic acid-induced α-synuclein oligomerization
Cheng, A., Shinoda, Y., Yamamoto, T., Miyachi, H., & Fukunaga, K. (2019) · Brain Research · doi:10.1016/j.brainres.2018.11.036 · Cited by 50
Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation
Chavarría, C., Ivagnes, R., & Souza, J. M. (2022) · Biomolecules · doi:10.3390/biom12050655 · Cited by 47
Relevance of chronic stress and the two faces of microglia in Parkinson's disease
Herrera, A. J., Espinosa-Oliva, A. M., Carrillo-Jiménez, A., Oliva-Martín, M. J., García-Revilla, J., García-Quintanilla, A., de Pablos, R. M., & Venero, J. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00312 · Cited by 42
Landeck, N., Strathearn, K. E., Ysselstein, D., Buck, K., Dutta, S., Banerjee, S., Lv, Z., Hulleman, J. D., Hindupur, J., Lin, L.-K., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00380-w · Cited by 19
Self-citationKonieczny, J., Lenda, T., & Czarnecka, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.072 · Cited by 12
Metadata
- Authors
- Volles, M. J., Lee, S.-J., Rochet, J.-C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., & Lansbury, P. T.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2001-06-09
- Volume
- 40
- Issue
- 26
- Pages
- 7812-7819
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2087389265
- Cited by
- 682
- References
- 11
- FWCI
- 23.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.